1. Patients aged 18-75 years, regardless of gender.
2. Diagnosed with HER2-positive breast cancer and currently receiving pyrotinib treatment (either as monotherapy or in combination with endocrine therapy), with a treatment duration of ≥ 2 weeks.
3. Voluntarily agree to participate in this study and provide written informed consent.
You may not be if
1. History of significant gastrointestinal diseases (e.g., inflammatory bowel disease, Crohn's disease, ulcerative colitis, intestinal obstruction) or previous major gastrointestinal surgery.
2. Recent use (within 1 month) of antibiotics, probiotics, or traditional Chinese medicine intended to alter intestinal function.
3. Pregnant or lactating women.
Clareo Health | Gut Microbiota and Diarrhea in Breast Cancer Patients Receiving Pyrotinib
